Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Publication year range
1.
Eur Urol Oncol ; 2024 02 13.
Article in English | MEDLINE | ID: mdl-38355375

ABSTRACT

BACKGROUND: The European Association of Urology (EAU) recommends discussing upfront radical cystectomy for all patients with very high risk (VHR) non-muscle-invasive bladder carcinoma (NMIBC), but the role of bacillus Calmette-Guérin (BCG) treatment remains controversial. OBJECTIVE: To analyze oncological outcomes in VHR NMIBC patients (EAU risk groups) treated with adequate BCG. DESIGN, SETTING, AND PARTICIPANTS: A multi-institutional retrospective study involving patients with VHR NMIBC who received adequate BCG therapy from 2007 to 2020 was conducted. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: A survival analysis estimated recurrence-free survival (RFS), progression-free survival (PFS), and the cumulative incidence of cancer-specific mortality (CSM) after accounting for other causes of mortality as competing risk events and of the overall mortality (OM). Conditional survival probabilities for 0-4 yr without events were computed. Cox regression assessed the predictors of oncological outcomes. RESULTS AND LIMITATION: A total of 640 patients, with a median 47 (32-67) mo follow-up for event-free individuals, were analyzed. High-grade RFS and PFS at 5 yr were 53% (49-57%) and 78% (74-82%), respectively. The cumulative incidence of CSM and OM at 5 yr was 13% (10-16%) and 16% (13-19%), respectively. Conditional RFS, PFS, overall survival, and cancer-specific survival at 4 yr were 91%, 96%, 87%, and 94%, respectively. Cox regression identified tumor grade (hazard ratio [HR]: 1.54; 1.1-2) and size (HR: 1.3; 1.1-1.7) as RFS predictors. Tumor multiplicity predicted RFS (HR: 1.6; 1.3-2), PFS (HR: 2; 1.2-3.3), and CSM (HR: 2; 1.2-3.2), while age predicted OM (HR: 1.48; 1.1-2). CONCLUSIONS: Patients with VHR NMIBC who receive adequate BCG therapy have a more favorable prognosis than predicted by EAU risk groups, especially among those with a sustained response, in whom continuing maintenance therapy emerges as a viable alternative to radical cystectomy. PATIENT SUMMARY: Our research shows that a sustained response to bacillus Calmette-Guérin in patients can lead to favorable outcomes, serving as a viable alternative to cystectomy for select cases.

2.
5.
Rev Chilena Infectol ; 37(3): 322-326, 2020 Jun.
Article in Spanish | MEDLINE | ID: mdl-32853327

ABSTRACT

Nocardiosis is a localized or systemic infection that mainly affects immunocompromised patients, with pulmonary localization being the most frequent site. The transmission comes mainly from the inhalation of spores or by direct inoculation into the skin and ocular mucosa. More than 90 species of nocardia are described, of which more than half are recognized as pathogens in humans. The best known species of medical importance are Nocardia farcinica, Nocardia abscessus, Nocardia nova y Nocardia brasiliensis. In Chile, there have been published cases of Nocardia asteroides and Nocardia farcinica infections. Nocardia cyriacigeorgica is considered an emerging species, there being no cases previously described in our country. We present a clinical case of pulmonary nocardiosis in an acquired immunodeficiency syndrome (AIDS) patient.


Subject(s)
Acquired Immunodeficiency Syndrome , Nocardia Infections , Chile , Humans , Nocardia
6.
Rev. chil. infectol ; 37(3): 322-326, jun. 2020. graf
Article in Spanish | LILACS | ID: biblio-1126127

ABSTRACT

Resumen La nocardiosis es una infección localizada o sistémica que afecta principalmente a pacientes inmunocomprometidos, siendo la localización pulmonar el sitio más frecuente. La transmisión proviene principalmente de la inhalación de esporas o mediante la inoculación directa en la piel y mucosa ocular. Se han descrito más de 90 especies de Nocardia, de éstas más de la mitad son reconocidas como patógenos en humanos. Las especies de importancia médica más conocidas son Nocardia farcinica, Nocardia abscessus, Nocardia nova y Nocardia brasiliensis. En Chile hay casos publicados de infección por Nocardia asteroides y N. farcinica. Nocardia cyriacigeorgica se considera una especie emergente, no habiendo casos descritos previamente en nuestro país. Presentamos el caso clínico de una nocardiosis pulmonar en un paciente con síndrome de inmunodeficiencia adquirida (SIDA).


Abstract Nocardiosis is a localized or systemic infection that mainly affects immunocompromised patients, with pulmonary localization being the most frequent site. The transmission comes mainly from the inhalation of spores or by direct inoculation into the skin and ocular mucosa. More than 90 species of nocardia are described, of which more than half are recognized as pathogens in humans. The best known species of medical importance are Nocardia farcinica, Nocardia abscessus, Nocardia nova y Nocardia brasiliensis. In Chile, there have been published cases of Nocardia asteroides and Nocardia farcinica infections. Nocardia cyriacigeorgica is considered an emerging species, there being no cases previously described in our country. We present a clinical case of pulmonary nocardiosis in an acquired immunodeficiency syndrome (AIDS) patient.


Subject(s)
Humans , Acquired Immunodeficiency Syndrome , Nocardia Infections , Chile , Nocardia
7.
Rev Chilena Infectol ; 36(5): 663-666, 2019 Oct.
Article in Spanish | MEDLINE | ID: mdl-31859809

ABSTRACT

Bacteremia is an atypical presentation of Campylobacter jejuni infection and it is more frequent in patients with advanced inmunodepression due to HIV or other sistemic diseases. Because of the highly active antiretroviral therapy, in the last decades the number of cases had declined. We report a case of a homeless woman with HIV in C3 stage who was diagnosed with the bacteremia during her hospitalization for pulmonary tuberculosis, and a brief review of C. jejuni bacteremia in HIV patients.


Subject(s)
AIDS-Related Opportunistic Infections/microbiology , Bacteremia/microbiology , Campylobacter Infections/microbiology , Campylobacter jejuni/isolation & purification , AIDS-Related Opportunistic Infections/drug therapy , AIDS-Related Opportunistic Infections/immunology , Adult , Anti-Bacterial Agents/therapeutic use , Bacteremia/drug therapy , Bacteremia/immunology , Campylobacter Infections/drug therapy , Campylobacter Infections/immunology , Female , Humans , Tuberculosis, Pulmonary/drug therapy
8.
Rev. chil. infectol ; 36(5): 663-666, oct. 2019. tab
Article in Spanish | LILACS | ID: biblio-1058093

ABSTRACT

Resumen La bacteriemia es una presentación atípica de la infección por Campylobacter jejuni, y es más frecuente en pacientes con inmunodepresión avanzada debido al VIH u otras enfermedades sistémicas. Debido a la terapia anti-retroviral, en las últimas décadas el número de casos ha disminuido. Presentamos el caso de una mujer en situación de calle, con VIH en etapa C3, que cursó con una bacteriemia por C. jejuni durante su hospitalización por una tuberculosis pulmonar. Realizamos una breve revisión de bacteriemia por C. jejuni en pacientes con VIH.


Bacteremia is an atypical presentation of Campylobacter jejuni infection and it is more frequent in patients with advanced inmunodepression due to HIV or other sistemic diseases. Because of the highly active antiretroviral therapy, in the last decades the number of cases had declined. We report a case of a homeless woman with HIV in C3 stage who was diagnosed with the bacteremia during her hospitalization for pulmonary tuberculosis, and a brief review of C. jejuni bacteremia in HIV patients.


Subject(s)
Humans , Female , Adult , Campylobacter Infections/microbiology , Campylobacter jejuni/isolation & purification , Bacteremia/microbiology , AIDS-Related Opportunistic Infections/microbiology , Tuberculosis, Pulmonary/drug therapy , Campylobacter Infections/immunology , Campylobacter Infections/drug therapy , Bacteremia/immunology , Bacteremia/drug therapy , AIDS-Related Opportunistic Infections/immunology , AIDS-Related Opportunistic Infections/drug therapy , Anti-Bacterial Agents/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...